nodes	percent_of_prediction	percent_of_DWPC	metapath
Flurbiprofen—PTGS2—bone cancer	0.398	1	CbGaD
Flurbiprofen—UGT2B7—Epirubicin—bone cancer	0.161	0.421	CbGbCtD
Flurbiprofen—ABCC4—Methotrexate—bone cancer	0.0731	0.192	CbGbCtD
Flurbiprofen—PTGS2—Cisplatin—bone cancer	0.0662	0.174	CbGbCtD
Flurbiprofen—SLC22A6—Methotrexate—bone cancer	0.0318	0.0834	CbGbCtD
Flurbiprofen—ALB—Methotrexate—bone cancer	0.0271	0.0711	CbGbCtD
Flurbiprofen—CYP2C9—Cisplatin—bone cancer	0.0225	0.059	CbGbCtD
Flurbiprofen—UGT2B4—Farnesoid X Receptor  Pathway—CYP3A4—bone cancer	0.00263	0.0456	CbGpPWpGaD
Flurbiprofen—UGT2B7—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.0024	0.0415	CbGpPWpGaD
Flurbiprofen—UGT2B4—Metapathway biotransformation—CYP4V2—bone cancer	0.00225	0.0391	CbGpPWpGaD
Flurbiprofen—ABCC4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00211	0.0366	CbGpPWpGaD
Flurbiprofen—UGT1A1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00195	0.0337	CbGpPWpGaD
Flurbiprofen—UGT1A3—Estrogen metabolism—CYP3A4—bone cancer	0.00147	0.0255	CbGpPWpGaD
Flurbiprofen—UGT2B7—Estrogen metabolism—CYP3A4—bone cancer	0.00125	0.0217	CbGpPWpGaD
Flurbiprofen—UGT1A1—Irinotecan Pathway—CYP3A4—bone cancer	0.00124	0.0216	CbGpPWpGaD
Flurbiprofen—UGT1A9—Irinotecan Pathway—CYP3A4—bone cancer	0.00124	0.0216	CbGpPWpGaD
Flurbiprofen—ABCC4—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.00123	0.0214	CbGpPWpGaD
Flurbiprofen—UGT1A3—Metapathway biotransformation—CYP4V2—bone cancer	0.00121	0.0209	CbGpPWpGaD
Flurbiprofen—UGT2B7—Tamoxifen metabolism—CYP3A4—bone cancer	0.00111	0.0192	CbGpPWpGaD
Flurbiprofen—UGT2B7—Metapathway biotransformation—CYP4V2—bone cancer	0.00103	0.0178	CbGpPWpGaD
Flurbiprofen—UGT1A1—Estrogen metabolism—CYP3A4—bone cancer	0.00102	0.0176	CbGpPWpGaD
Flurbiprofen—UGT1A9—Estrogen metabolism—CYP3A4—bone cancer	0.00102	0.0176	CbGpPWpGaD
Flurbiprofen—UGT1A3—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000929	0.0161	CbGpPWpGaD
Flurbiprofen—ABCC4—Ectoderm Differentiation—BCOR—bone cancer	0.000884	0.0153	CbGpPWpGaD
Flurbiprofen—ABCC4—Fluoropyrimidine Activity—DHFR—bone cancer	0.000855	0.0148	CbGpPWpGaD
Flurbiprofen—UGT1A1—Metapathway biotransformation—CYP4V2—bone cancer	0.000834	0.0145	CbGpPWpGaD
Flurbiprofen—UGT1A9—Metapathway biotransformation—CYP4V2—bone cancer	0.000834	0.0145	CbGpPWpGaD
Flurbiprofen—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00083	0.0144	CbGpPWpGaD
Flurbiprofen—ALB—Folate Metabolism—FOLR1—bone cancer	0.00081	0.014	CbGpPWpGaD
Flurbiprofen—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000794	0.0138	CbGpPWpGaD
Flurbiprofen—UGT2B4—Phase II conjugation—GSTP1—bone cancer	0.000661	0.0114	CbGpPWpGaD
Flurbiprofen—UGT1A1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000642	0.0111	CbGpPWpGaD
Flurbiprofen—UGT1A9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000642	0.0111	CbGpPWpGaD
Flurbiprofen—Carprofen—PTGS2—bone cancer	0.00061	0.106	CrCbGaD
Flurbiprofen—Tiaprofenic acid—PTGS2—bone cancer	0.000497	0.0865	CrCbGaD
Flurbiprofen—UGT1A9—PPAR Alpha Pathway—CDK4—bone cancer	0.00047	0.00815	CbGpPWpGaD
Flurbiprofen—Fenbufen—PTGS2—bone cancer	0.000452	0.0787	CrCbGaD
Flurbiprofen—UGT2B4—Biological oxidations—CYP3A4—bone cancer	0.000452	0.00783	CbGpPWpGaD
Flurbiprofen—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL3—bone cancer	0.00045	0.00779	CbGpPWpGaD
Flurbiprofen—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—bone cancer	0.000449	0.00779	CbGpPWpGaD
Flurbiprofen—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000449	0.00778	CbGpPWpGaD
Flurbiprofen—UGT2B4—Metapathway biotransformation—CYP3A4—bone cancer	0.000446	0.00772	CbGpPWpGaD
Flurbiprofen—Diflunisal—PTGS2—bone cancer	0.000435	0.0756	CrCbGaD
Flurbiprofen—ABCC4—Platelet degranulation—SPARC—bone cancer	0.00043	0.00746	CbGpPWpGaD
Flurbiprofen—ABCC4—Response to elevated platelet cytosolic Ca2+—SPARC—bone cancer	0.00041	0.00711	CbGpPWpGaD
Flurbiprofen—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000401	0.00695	CbGpPWpGaD
Flurbiprofen—PTGS2—Signaling mediated by p38-alpha and p38-beta—ATF1—bone cancer	0.000397	0.00687	CbGpPWpGaD
Flurbiprofen—Oxaprozin—PTGS2—bone cancer	0.000393	0.0684	CrCbGaD
Flurbiprofen—Salsalate—PTGS2—bone cancer	0.000393	0.0684	CrCbGaD
Flurbiprofen—UGT2B4—Biological oxidations—GSTP1—bone cancer	0.000386	0.0067	CbGpPWpGaD
Flurbiprofen—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000385	0.00668	CbGpPWpGaD
Flurbiprofen—UGT2B4—Metapathway biotransformation—GSTP1—bone cancer	0.000381	0.0066	CbGpPWpGaD
Flurbiprofen—Suprofen—PTGS2—bone cancer	0.000377	0.0656	CrCbGaD
Flurbiprofen—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000357	0.00619	CbGpPWpGaD
Flurbiprofen—UGT1A3—Phase II conjugation—GSTP1—bone cancer	0.000354	0.00613	CbGpPWpGaD
Flurbiprofen—PTGS1—Overview of nanoparticle effects—PTGS2—bone cancer	0.000352	0.0061	CbGpPWpGaD
Flurbiprofen—ALB—Binding and Uptake of Ligands by Scavenger Receptors—SPARC—bone cancer	0.000333	0.00576	CbGpPWpGaD
Flurbiprofen—Fenoprofen—PTGS2—bone cancer	0.000325	0.0565	CrCbGaD
Flurbiprofen—Mefenamic acid—PTGS2—bone cancer	0.000301	0.0524	CrCbGaD
Flurbiprofen—UGT2B7—Phase II conjugation—GSTP1—bone cancer	0.000301	0.00521	CbGpPWpGaD
Flurbiprofen—Naproxen—PTGS2—bone cancer	0.000296	0.0515	CrCbGaD
Flurbiprofen—PTGS1—Eicosanoid Synthesis—PTGS2—bone cancer	0.000292	0.00506	CbGpPWpGaD
Flurbiprofen—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL3—bone cancer	0.000291	0.00504	CbGpPWpGaD
Flurbiprofen—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—bone cancer	0.000289	0.00501	CbGpPWpGaD
Flurbiprofen—UGT1A3—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000278	0.00481	CbGpPWpGaD
Flurbiprofen—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000275	0.00477	CbGpPWpGaD
Flurbiprofen—UGT2B4—Metabolism—NDUFA12—bone cancer	0.000271	0.00469	CbGpPWpGaD
Flurbiprofen—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000262	0.00454	CbGpPWpGaD
Flurbiprofen—PTGS1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000257	0.00445	CbGpPWpGaD
Flurbiprofen—Warfarin—CYP3A4—bone cancer	0.000254	0.0442	CrCbGaD
Flurbiprofen—UGT1A9—Phase II conjugation—GSTP1—bone cancer	0.000244	0.00424	CbGpPWpGaD
Flurbiprofen—UGT1A1—Phase II conjugation—GSTP1—bone cancer	0.000244	0.00424	CbGpPWpGaD
Flurbiprofen—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	0.000244	0.00423	CbGpPWpGaD
Flurbiprofen—UGT1A3—Biological oxidations—CYP3A4—bone cancer	0.000242	0.00419	CbGpPWpGaD
Flurbiprofen—Chlordiazepoxide—CYP3A4—bone cancer	0.000239	0.0415	CrCbGaD
Flurbiprofen—UGT1A3—Metapathway biotransformation—CYP3A4—bone cancer	0.000239	0.00414	CbGpPWpGaD
Flurbiprofen—UGT1A3—NRF2 pathway—TGFBR2—bone cancer	0.000236	0.00409	CbGpPWpGaD
Flurbiprofen—UGT1A3—NRF2 pathway—GSTP1—bone cancer	0.000236	0.00409	CbGpPWpGaD
Flurbiprofen—UGT2B4—Metabolism—NT5C3A—bone cancer	0.000224	0.00389	CbGpPWpGaD
Flurbiprofen—Clorazepate—CYP3A4—bone cancer	0.000223	0.0389	CrCbGaD
Flurbiprofen—ALB—Folate Metabolism—DHFR—bone cancer	0.000222	0.00385	CbGpPWpGaD
Flurbiprofen—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—DHFR—bone cancer	0.00022	0.00382	CbGpPWpGaD
Flurbiprofen—UGT1A3—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000218	0.00378	CbGpPWpGaD
Flurbiprofen—Erectile dysfunction—Methotrexate—bone cancer	0.000217	0.00139	CcSEcCtD
Flurbiprofen—Dry skin—Doxorubicin—bone cancer	0.000217	0.00138	CcSEcCtD
Flurbiprofen—Pancreatitis—Epirubicin—bone cancer	0.000216	0.00138	CcSEcCtD
Flurbiprofen—Photosensitivity reaction—Methotrexate—bone cancer	0.000215	0.00137	CcSEcCtD
Flurbiprofen—Angina pectoris—Epirubicin—bone cancer	0.000215	0.00137	CcSEcCtD
Flurbiprofen—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.000213	0.00136	CcSEcCtD
Flurbiprofen—Decreased appetite—Cisplatin—bone cancer	0.000212	0.00135	CcSEcCtD
Flurbiprofen—Bronchitis—Epirubicin—bone cancer	0.000212	0.00135	CcSEcCtD
Flurbiprofen—Pneumonia—Methotrexate—bone cancer	0.000211	0.00135	CcSEcCtD
Flurbiprofen—Drowsiness—Methotrexate—bone cancer	0.00021	0.00134	CcSEcCtD
Flurbiprofen—Pancytopenia—Epirubicin—bone cancer	0.00021	0.00134	CcSEcCtD
Flurbiprofen—Gastritis—Doxorubicin—bone cancer	0.000209	0.00133	CcSEcCtD
Flurbiprofen—Pain—Cisplatin—bone cancer	0.000209	0.00133	CcSEcCtD
Flurbiprofen—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000208	0.00133	CcSEcCtD
Flurbiprofen—Muscular weakness—Doxorubicin—bone cancer	0.000208	0.00133	CcSEcCtD
Flurbiprofen—UGT1A3—Biological oxidations—GSTP1—bone cancer	0.000207	0.00359	CbGpPWpGaD
Flurbiprofen—Renal failure—Methotrexate—bone cancer	0.000207	0.00132	CcSEcCtD
Flurbiprofen—Dysuria—Epirubicin—bone cancer	0.000206	0.00132	CcSEcCtD
Flurbiprofen—Neutropenia—Epirubicin—bone cancer	0.000206	0.00132	CcSEcCtD
Flurbiprofen—UGT2B7—Biological oxidations—CYP3A4—bone cancer	0.000206	0.00357	CbGpPWpGaD
Flurbiprofen—Abdominal distension—Doxorubicin—bone cancer	0.000206	0.00131	CcSEcCtD
Flurbiprofen—Stomatitis—Methotrexate—bone cancer	0.000205	0.00131	CcSEcCtD
Flurbiprofen—Conjunctivitis—Methotrexate—bone cancer	0.000204	0.0013	CcSEcCtD
Flurbiprofen—Asthma—Doxorubicin—bone cancer	0.000204	0.0013	CcSEcCtD
Flurbiprofen—Influenza—Doxorubicin—bone cancer	0.000204	0.0013	CcSEcCtD
Flurbiprofen—UGT1A3—Metapathway biotransformation—GSTP1—bone cancer	0.000204	0.00354	CbGpPWpGaD
Flurbiprofen—UGT2B7—Metapathway biotransformation—CYP3A4—bone cancer	0.000203	0.00352	CbGpPWpGaD
Flurbiprofen—Eosinophilia—Doxorubicin—bone cancer	0.000202	0.00129	CcSEcCtD
Flurbiprofen—Sweating—Methotrexate—bone cancer	0.000202	0.00129	CcSEcCtD
Flurbiprofen—Photosensitivity reaction—Epirubicin—bone cancer	0.000201	0.00128	CcSEcCtD
Flurbiprofen—Feeling abnormal—Cisplatin—bone cancer	0.000201	0.00128	CcSEcCtD
Flurbiprofen—UGT2B7—NRF2 pathway—GSTP1—bone cancer	0.000201	0.00348	CbGpPWpGaD
Flurbiprofen—UGT2B7—NRF2 pathway—TGFBR2—bone cancer	0.000201	0.00348	CbGpPWpGaD
Flurbiprofen—Haematuria—Methotrexate—bone cancer	0.0002	0.00128	CcSEcCtD
Flurbiprofen—Pancreatitis—Doxorubicin—bone cancer	0.0002	0.00128	CcSEcCtD
Flurbiprofen—Hyperglycaemia—Epirubicin—bone cancer	0.000199	0.00127	CcSEcCtD
Flurbiprofen—Angina pectoris—Doxorubicin—bone cancer	0.000199	0.00127	CcSEcCtD
Flurbiprofen—Epistaxis—Methotrexate—bone cancer	0.000198	0.00126	CcSEcCtD
Flurbiprofen—Pneumonia—Epirubicin—bone cancer	0.000198	0.00126	CcSEcCtD
Flurbiprofen—Drowsiness—Epirubicin—bone cancer	0.000197	0.00126	CcSEcCtD
Flurbiprofen—Bronchitis—Doxorubicin—bone cancer	0.000196	0.00125	CcSEcCtD
Flurbiprofen—Agranulocytosis—Methotrexate—bone cancer	0.000196	0.00125	CcSEcCtD
Flurbiprofen—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000195	0.00124	CcSEcCtD
Flurbiprofen—ALB—Platelet degranulation—SPARC—bone cancer	0.000195	0.00338	CbGpPWpGaD
Flurbiprofen—Pancytopenia—Doxorubicin—bone cancer	0.000194	0.00124	CcSEcCtD
Flurbiprofen—Renal failure—Epirubicin—bone cancer	0.000193	0.00123	CcSEcCtD
Flurbiprofen—Body temperature increased—Cisplatin—bone cancer	0.000193	0.00123	CcSEcCtD
Flurbiprofen—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000192	0.00333	CbGpPWpGaD
Flurbiprofen—UGT1A9—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000192	0.00333	CbGpPWpGaD
Flurbiprofen—Stomatitis—Epirubicin—bone cancer	0.000192	0.00122	CcSEcCtD
Flurbiprofen—Jaundice—Epirubicin—bone cancer	0.000192	0.00122	CcSEcCtD
Flurbiprofen—Ketoprofen—PTGS2—bone cancer	0.000192	0.0334	CrCbGaD
Flurbiprofen—Urinary tract infection—Epirubicin—bone cancer	0.000191	0.00122	CcSEcCtD
Flurbiprofen—Conjunctivitis—Epirubicin—bone cancer	0.000191	0.00122	CcSEcCtD
Flurbiprofen—ABCC4—Fluoropyrimidine Activity—TP53—bone cancer	0.000191	0.00331	CbGpPWpGaD
Flurbiprofen—Neutropenia—Doxorubicin—bone cancer	0.000191	0.00122	CcSEcCtD
Flurbiprofen—Dysuria—Doxorubicin—bone cancer	0.000191	0.00122	CcSEcCtD
Flurbiprofen—ABCC4—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.000191	0.00331	CbGpPWpGaD
Flurbiprofen—Haemoglobin—Methotrexate—bone cancer	0.00019	0.00121	CcSEcCtD
Flurbiprofen—Hepatitis—Methotrexate—bone cancer	0.000189	0.0012	CcSEcCtD
Flurbiprofen—Haemorrhage—Methotrexate—bone cancer	0.000189	0.0012	CcSEcCtD
Flurbiprofen—Ibuprofen—PTGS2—bone cancer	0.000189	0.0328	CrCbGaD
Flurbiprofen—ABCC4—NRF2 pathway—TGFBR2—bone cancer	0.000189	0.00327	CbGpPWpGaD
Flurbiprofen—ABCC4—NRF2 pathway—GSTP1—bone cancer	0.000189	0.00327	CbGpPWpGaD
Flurbiprofen—Sweating—Epirubicin—bone cancer	0.000189	0.0012	CcSEcCtD
Flurbiprofen—Haematuria—Epirubicin—bone cancer	0.000188	0.0012	CcSEcCtD
Flurbiprofen—Pharyngitis—Methotrexate—bone cancer	0.000187	0.00119	CcSEcCtD
Flurbiprofen—Photosensitivity reaction—Doxorubicin—bone cancer	0.000186	0.00119	CcSEcCtD
Flurbiprofen—Epistaxis—Epirubicin—bone cancer	0.000186	0.00118	CcSEcCtD
Flurbiprofen—ALB—Response to elevated platelet cytosolic Ca2+—SPARC—bone cancer	0.000186	0.00322	CbGpPWpGaD
Flurbiprofen—Sinusitis—Epirubicin—bone cancer	0.000185	0.00118	CcSEcCtD
Flurbiprofen—Hyperglycaemia—Doxorubicin—bone cancer	0.000184	0.00117	CcSEcCtD
Flurbiprofen—Agranulocytosis—Epirubicin—bone cancer	0.000184	0.00117	CcSEcCtD
Flurbiprofen—Pneumonia—Doxorubicin—bone cancer	0.000183	0.00117	CcSEcCtD
Flurbiprofen—Drowsiness—Doxorubicin—bone cancer	0.000182	0.00116	CcSEcCtD
Flurbiprofen—Visual impairment—Methotrexate—bone cancer	0.000182	0.00116	CcSEcCtD
Flurbiprofen—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000181	0.00115	CcSEcCtD
Flurbiprofen—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—bone cancer	0.00018	0.00312	CbGpPWpGaD
Flurbiprofen—Hypersensitivity—Cisplatin—bone cancer	0.00018	0.00115	CcSEcCtD
Flurbiprofen—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—bone cancer	0.00018	0.00311	CbGpPWpGaD
Flurbiprofen—Renal failure—Doxorubicin—bone cancer	0.000179	0.00114	CcSEcCtD
Flurbiprofen—Erythema multiforme—Methotrexate—bone cancer	0.000178	0.00114	CcSEcCtD
Flurbiprofen—Haemoglobin—Epirubicin—bone cancer	0.000178	0.00113	CcSEcCtD
Flurbiprofen—Stomatitis—Doxorubicin—bone cancer	0.000177	0.00113	CcSEcCtD
Flurbiprofen—Jaundice—Doxorubicin—bone cancer	0.000177	0.00113	CcSEcCtD
Flurbiprofen—Rhinitis—Epirubicin—bone cancer	0.000177	0.00113	CcSEcCtD
Flurbiprofen—Conjunctivitis—Doxorubicin—bone cancer	0.000177	0.00113	CcSEcCtD
Flurbiprofen—Urinary tract infection—Doxorubicin—bone cancer	0.000177	0.00113	CcSEcCtD
Flurbiprofen—Haemorrhage—Epirubicin—bone cancer	0.000177	0.00113	CcSEcCtD
Flurbiprofen—Hepatitis—Epirubicin—bone cancer	0.000177	0.00113	CcSEcCtD
Flurbiprofen—UGT2B7—Biological oxidations—GSTP1—bone cancer	0.000176	0.00305	CbGpPWpGaD
Flurbiprofen—Tinnitus—Methotrexate—bone cancer	0.000176	0.00112	CcSEcCtD
Flurbiprofen—Asthenia—Cisplatin—bone cancer	0.000175	0.00112	CcSEcCtD
Flurbiprofen—Pharyngitis—Epirubicin—bone cancer	0.000175	0.00112	CcSEcCtD
Flurbiprofen—ABCC4—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.000175	0.00303	CbGpPWpGaD
Flurbiprofen—Sweating—Doxorubicin—bone cancer	0.000175	0.00111	CcSEcCtD
Flurbiprofen—Haematuria—Doxorubicin—bone cancer	0.000174	0.00111	CcSEcCtD
Flurbiprofen—UGT2B7—Metapathway biotransformation—GSTP1—bone cancer	0.000174	0.00301	CbGpPWpGaD
Flurbiprofen—Epistaxis—Doxorubicin—bone cancer	0.000172	0.0011	CcSEcCtD
Flurbiprofen—Angiopathy—Methotrexate—bone cancer	0.000171	0.00109	CcSEcCtD
Flurbiprofen—Sinusitis—Doxorubicin—bone cancer	0.000171	0.00109	CcSEcCtD
Flurbiprofen—Visual impairment—Epirubicin—bone cancer	0.00017	0.00109	CcSEcCtD
Flurbiprofen—Agranulocytosis—Doxorubicin—bone cancer	0.00017	0.00108	CcSEcCtD
Flurbiprofen—Chills—Methotrexate—bone cancer	0.000169	0.00108	CcSEcCtD
Flurbiprofen—PTGS2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000168	0.0029	CbGpPWpGaD
Flurbiprofen—UGT1A1—Biological oxidations—CYP3A4—bone cancer	0.000167	0.0029	CbGpPWpGaD
Flurbiprofen—UGT1A9—Biological oxidations—CYP3A4—bone cancer	0.000167	0.0029	CbGpPWpGaD
Flurbiprofen—Diarrhoea—Cisplatin—bone cancer	0.000167	0.00107	CcSEcCtD
Flurbiprofen—Nitrazepam—CYP3A4—bone cancer	0.000167	0.0291	CrCbGaD
Flurbiprofen—Erythema multiforme—Epirubicin—bone cancer	0.000167	0.00107	CcSEcCtD
Flurbiprofen—Alopecia—Methotrexate—bone cancer	0.000167	0.00106	CcSEcCtD
Flurbiprofen—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000166	0.00288	CbGpPWpGaD
Flurbiprofen—UGT1A1—Metapathway biotransformation—CYP3A4—bone cancer	0.000165	0.00286	CbGpPWpGaD
Flurbiprofen—UGT1A9—Metapathway biotransformation—CYP3A4—bone cancer	0.000165	0.00286	CbGpPWpGaD
Flurbiprofen—Tinnitus—Epirubicin—bone cancer	0.000165	0.00105	CcSEcCtD
Flurbiprofen—Haemoglobin—Doxorubicin—bone cancer	0.000164	0.00105	CcSEcCtD
Flurbiprofen—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000164	0.00285	CbGpPWpGaD
Flurbiprofen—Rhinitis—Doxorubicin—bone cancer	0.000164	0.00105	CcSEcCtD
Flurbiprofen—Haemorrhage—Doxorubicin—bone cancer	0.000163	0.00104	CcSEcCtD
Flurbiprofen—Hepatitis—Doxorubicin—bone cancer	0.000163	0.00104	CcSEcCtD
Flurbiprofen—UGT1A1—NRF2 pathway—GSTP1—bone cancer	0.000163	0.00283	CbGpPWpGaD
Flurbiprofen—UGT1A1—NRF2 pathway—TGFBR2—bone cancer	0.000163	0.00283	CbGpPWpGaD
Flurbiprofen—UGT1A9—NRF2 pathway—TGFBR2—bone cancer	0.000163	0.00283	CbGpPWpGaD
Flurbiprofen—UGT1A9—NRF2 pathway—GSTP1—bone cancer	0.000163	0.00283	CbGpPWpGaD
Flurbiprofen—PTGS1—Arachidonic acid metabolism—PTGS2—bone cancer	0.000162	0.00281	CbGpPWpGaD
Flurbiprofen—Pharyngitis—Doxorubicin—bone cancer	0.000162	0.00103	CcSEcCtD
Flurbiprofen—Angiopathy—Epirubicin—bone cancer	0.00016	0.00102	CcSEcCtD
Flurbiprofen—Chills—Epirubicin—bone cancer	0.000158	0.00101	CcSEcCtD
Flurbiprofen—ABCC4—Platelet activation, signaling and aggregation—IL3—bone cancer	0.000158	0.00274	CbGpPWpGaD
Flurbiprofen—Arrhythmia—Epirubicin—bone cancer	0.000158	0.00101	CcSEcCtD
Flurbiprofen—Visual impairment—Doxorubicin—bone cancer	0.000158	0.001	CcSEcCtD
Flurbiprofen—Alopecia—Epirubicin—bone cancer	0.000156	0.000996	CcSEcCtD
Flurbiprofen—Vomiting—Cisplatin—bone cancer	0.000155	0.000991	CcSEcCtD
Flurbiprofen—Erythema multiforme—Doxorubicin—bone cancer	0.000155	0.000986	CcSEcCtD
Flurbiprofen—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—bone cancer	0.000155	0.00268	CbGpPWpGaD
Flurbiprofen—Rash—Cisplatin—bone cancer	0.000154	0.000983	CcSEcCtD
Flurbiprofen—Dermatitis—Cisplatin—bone cancer	0.000154	0.000982	CcSEcCtD
Flurbiprofen—Ill-defined disorder—Methotrexate—bone cancer	0.000152	0.000972	CcSEcCtD
Flurbiprofen—Tinnitus—Doxorubicin—bone cancer	0.000152	0.000972	CcSEcCtD
Flurbiprofen—Anaemia—Methotrexate—bone cancer	0.000152	0.000969	CcSEcCtD
Flurbiprofen—Flatulence—Epirubicin—bone cancer	0.000152	0.000966	CcSEcCtD
Flurbiprofen—Tension—Epirubicin—bone cancer	0.000151	0.000962	CcSEcCtD
Flurbiprofen—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000151	0.00261	CbGpPWpGaD
Flurbiprofen—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000151	0.00261	CbGpPWpGaD
Flurbiprofen—Nervousness—Epirubicin—bone cancer	0.000149	0.000953	CcSEcCtD
Flurbiprofen—ABCC4—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000148	0.00257	CbGpPWpGaD
Flurbiprofen—Angiopathy—Doxorubicin—bone cancer	0.000148	0.000946	CcSEcCtD
Flurbiprofen—Malaise—Methotrexate—bone cancer	0.000148	0.000945	CcSEcCtD
Flurbiprofen—Vertigo—Methotrexate—bone cancer	0.000148	0.000942	CcSEcCtD
Flurbiprofen—Leukopenia—Methotrexate—bone cancer	0.000147	0.000938	CcSEcCtD
Flurbiprofen—Chills—Doxorubicin—bone cancer	0.000147	0.000935	CcSEcCtD
Flurbiprofen—Arrhythmia—Doxorubicin—bone cancer	0.000146	0.000931	CcSEcCtD
Flurbiprofen—Nausea—Cisplatin—bone cancer	0.000145	0.000926	CcSEcCtD
Flurbiprofen—UGT1A3—Metabolism—NDUFA12—bone cancer	0.000145	0.00251	CbGpPWpGaD
Flurbiprofen—Alopecia—Doxorubicin—bone cancer	0.000144	0.000921	CcSEcCtD
Flurbiprofen—Oxazepam—CYP3A4—bone cancer	0.000144	0.025	CrCbGaD
Flurbiprofen—Cough—Methotrexate—bone cancer	0.000143	0.000915	CcSEcCtD
Flurbiprofen—UGT1A1—Biological oxidations—GSTP1—bone cancer	0.000143	0.00248	CbGpPWpGaD
Flurbiprofen—UGT1A9—Biological oxidations—GSTP1—bone cancer	0.000143	0.00248	CbGpPWpGaD
Flurbiprofen—Ill-defined disorder—Epirubicin—bone cancer	0.000143	0.00091	CcSEcCtD
Flurbiprofen—Convulsion—Methotrexate—bone cancer	0.000142	0.000908	CcSEcCtD
Flurbiprofen—Anaemia—Epirubicin—bone cancer	0.000142	0.000907	CcSEcCtD
Flurbiprofen—Temazepam—CYP3A4—bone cancer	0.000142	0.0247	CrCbGaD
Flurbiprofen—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000141	0.00245	CbGpPWpGaD
Flurbiprofen—UGT1A1—Metapathway biotransformation—GSTP1—bone cancer	0.000141	0.00244	CbGpPWpGaD
Flurbiprofen—UGT1A9—Metapathway biotransformation—GSTP1—bone cancer	0.000141	0.00244	CbGpPWpGaD
Flurbiprofen—Flatulence—Doxorubicin—bone cancer	0.00014	0.000894	CcSEcCtD
Flurbiprofen—Myalgia—Methotrexate—bone cancer	0.00014	0.000892	CcSEcCtD
Flurbiprofen—Tension—Doxorubicin—bone cancer	0.00014	0.000891	CcSEcCtD
Flurbiprofen—Malaise—Epirubicin—bone cancer	0.000139	0.000884	CcSEcCtD
Flurbiprofen—Discomfort—Methotrexate—bone cancer	0.000138	0.000882	CcSEcCtD
Flurbiprofen—Nervousness—Doxorubicin—bone cancer	0.000138	0.000881	CcSEcCtD
Flurbiprofen—Vertigo—Epirubicin—bone cancer	0.000138	0.000881	CcSEcCtD
Flurbiprofen—Syncope—Epirubicin—bone cancer	0.000138	0.00088	CcSEcCtD
Flurbiprofen—Leukopenia—Epirubicin—bone cancer	0.000138	0.000878	CcSEcCtD
Flurbiprofen—PTGS1—Biological oxidations—CYP3A4—bone cancer	0.000136	0.00236	CbGpPWpGaD
Flurbiprofen—Palpitations—Epirubicin—bone cancer	0.000136	0.000867	CcSEcCtD
Flurbiprofen—Confusional state—Methotrexate—bone cancer	0.000135	0.000862	CcSEcCtD
Flurbiprofen—Loss of consciousness—Epirubicin—bone cancer	0.000135	0.000862	CcSEcCtD
Flurbiprofen—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000135	0.00234	CbGpPWpGaD
Flurbiprofen—Cough—Epirubicin—bone cancer	0.000134	0.000856	CcSEcCtD
Flurbiprofen—Anaphylactic shock—Methotrexate—bone cancer	0.000134	0.000855	CcSEcCtD
Flurbiprofen—Convulsion—Epirubicin—bone cancer	0.000133	0.00085	CcSEcCtD
Flurbiprofen—Infection—Methotrexate—bone cancer	0.000133	0.00085	CcSEcCtD
Flurbiprofen—Hypertension—Epirubicin—bone cancer	0.000133	0.000847	CcSEcCtD
Flurbiprofen—Ill-defined disorder—Doxorubicin—bone cancer	0.000132	0.000842	CcSEcCtD
Flurbiprofen—Anaemia—Doxorubicin—bone cancer	0.000132	0.000839	CcSEcCtD
Flurbiprofen—Thrombocytopenia—Methotrexate—bone cancer	0.000131	0.000837	CcSEcCtD
Flurbiprofen—Myalgia—Epirubicin—bone cancer	0.000131	0.000835	CcSEcCtD
Flurbiprofen—Anxiety—Epirubicin—bone cancer	0.00013	0.000832	CcSEcCtD
Flurbiprofen—Hyperhidrosis—Methotrexate—bone cancer	0.00013	0.000827	CcSEcCtD
Flurbiprofen—Discomfort—Epirubicin—bone cancer	0.000129	0.000825	CcSEcCtD
Flurbiprofen—SLC22A6—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000129	0.00224	CbGpPWpGaD
Flurbiprofen—Malaise—Doxorubicin—bone cancer	0.000128	0.000818	CcSEcCtD
Flurbiprofen—ABCC4—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000128	0.00222	CbGpPWpGaD
Flurbiprofen—Dry mouth—Epirubicin—bone cancer	0.000128	0.000817	CcSEcCtD
Flurbiprofen—Vertigo—Doxorubicin—bone cancer	0.000128	0.000815	CcSEcCtD
Flurbiprofen—Anorexia—Methotrexate—bone cancer	0.000128	0.000815	CcSEcCtD
Flurbiprofen—Syncope—Doxorubicin—bone cancer	0.000128	0.000814	CcSEcCtD
Flurbiprofen—Leukopenia—Doxorubicin—bone cancer	0.000127	0.000812	CcSEcCtD
Flurbiprofen—Confusional state—Epirubicin—bone cancer	0.000127	0.000807	CcSEcCtD
Flurbiprofen—Palpitations—Doxorubicin—bone cancer	0.000126	0.000802	CcSEcCtD
Flurbiprofen—Anaphylactic shock—Epirubicin—bone cancer	0.000125	0.0008	CcSEcCtD
Flurbiprofen—Oedema—Epirubicin—bone cancer	0.000125	0.0008	CcSEcCtD
Flurbiprofen—Hypotension—Methotrexate—bone cancer	0.000125	0.000799	CcSEcCtD
Flurbiprofen—Loss of consciousness—Doxorubicin—bone cancer	0.000125	0.000798	CcSEcCtD
Flurbiprofen—Infection—Epirubicin—bone cancer	0.000125	0.000795	CcSEcCtD
Flurbiprofen—Cough—Doxorubicin—bone cancer	0.000124	0.000792	CcSEcCtD
Flurbiprofen—Shock—Epirubicin—bone cancer	0.000123	0.000788	CcSEcCtD
Flurbiprofen—UGT2B7—Metabolism—NDUFA12—bone cancer	0.000123	0.00214	CbGpPWpGaD
Flurbiprofen—Convulsion—Doxorubicin—bone cancer	0.000123	0.000786	CcSEcCtD
Flurbiprofen—Thrombocytopenia—Epirubicin—bone cancer	0.000123	0.000784	CcSEcCtD
Flurbiprofen—Hypertension—Doxorubicin—bone cancer	0.000123	0.000784	CcSEcCtD
Flurbiprofen—Tachycardia—Epirubicin—bone cancer	0.000122	0.000781	CcSEcCtD
Flurbiprofen—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000122	0.000779	CcSEcCtD
Flurbiprofen—Hyperhidrosis—Epirubicin—bone cancer	0.000121	0.000774	CcSEcCtD
Flurbiprofen—Insomnia—Methotrexate—bone cancer	0.000121	0.000774	CcSEcCtD
Flurbiprofen—Myalgia—Doxorubicin—bone cancer	0.000121	0.000773	CcSEcCtD
Flurbiprofen—Anxiety—Doxorubicin—bone cancer	0.000121	0.00077	CcSEcCtD
Flurbiprofen—Paraesthesia—Methotrexate—bone cancer	0.00012	0.000768	CcSEcCtD
Flurbiprofen—UGT1A3—Metabolism—NT5C3A—bone cancer	0.00012	0.00208	CbGpPWpGaD
Flurbiprofen—PTGS2—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.00012	0.00208	CbGpPWpGaD
Flurbiprofen—Discomfort—Doxorubicin—bone cancer	0.00012	0.000763	CcSEcCtD
Flurbiprofen—Anorexia—Epirubicin—bone cancer	0.00012	0.000763	CcSEcCtD
Flurbiprofen—Dyspnoea—Methotrexate—bone cancer	0.00012	0.000763	CcSEcCtD
Flurbiprofen—Somnolence—Methotrexate—bone cancer	0.000119	0.00076	CcSEcCtD
Flurbiprofen—Dry mouth—Doxorubicin—bone cancer	0.000118	0.000756	CcSEcCtD
Flurbiprofen—Diazepam—CYP3A4—bone cancer	0.000118	0.0205	CrCbGaD
Flurbiprofen—Dyspepsia—Methotrexate—bone cancer	0.000118	0.000753	CcSEcCtD
Flurbiprofen—Hypotension—Epirubicin—bone cancer	0.000117	0.000748	CcSEcCtD
Flurbiprofen—Confusional state—Doxorubicin—bone cancer	0.000117	0.000747	CcSEcCtD
Flurbiprofen—PTGS1—Biological oxidations—GSTP1—bone cancer	0.000117	0.00202	CbGpPWpGaD
Flurbiprofen—Decreased appetite—Methotrexate—bone cancer	0.000117	0.000744	CcSEcCtD
Flurbiprofen—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—bone cancer	0.000116	0.00201	CbGpPWpGaD
Flurbiprofen—Anaphylactic shock—Doxorubicin—bone cancer	0.000116	0.000741	CcSEcCtD
Flurbiprofen—Oedema—Doxorubicin—bone cancer	0.000116	0.000741	CcSEcCtD
Flurbiprofen—Infection—Doxorubicin—bone cancer	0.000115	0.000736	CcSEcCtD
Flurbiprofen—Pain—Methotrexate—bone cancer	0.000115	0.000731	CcSEcCtD
Flurbiprofen—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000114	0.000729	CcSEcCtD
Flurbiprofen—Shock—Doxorubicin—bone cancer	0.000114	0.000729	CcSEcCtD
Flurbiprofen—Thrombocytopenia—Doxorubicin—bone cancer	0.000114	0.000725	CcSEcCtD
Flurbiprofen—Insomnia—Epirubicin—bone cancer	0.000114	0.000724	CcSEcCtD
Flurbiprofen—Tachycardia—Doxorubicin—bone cancer	0.000113	0.000723	CcSEcCtD
Flurbiprofen—Paraesthesia—Epirubicin—bone cancer	0.000113	0.000719	CcSEcCtD
Flurbiprofen—Hyperhidrosis—Doxorubicin—bone cancer	0.000112	0.000716	CcSEcCtD
Flurbiprofen—PTGS2—C-MYB transcription factor network—KIT—bone cancer	0.000112	0.00194	CbGpPWpGaD
Flurbiprofen—Dyspnoea—Epirubicin—bone cancer	0.000112	0.000714	CcSEcCtD
Flurbiprofen—Somnolence—Epirubicin—bone cancer	0.000112	0.000712	CcSEcCtD
Flurbiprofen—SLC22A6—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000111	0.00193	CbGpPWpGaD
Flurbiprofen—Anorexia—Doxorubicin—bone cancer	0.000111	0.000706	CcSEcCtD
Flurbiprofen—Feeling abnormal—Methotrexate—bone cancer	0.000111	0.000705	CcSEcCtD
Flurbiprofen—Dyspepsia—Epirubicin—bone cancer	0.00011	0.000705	CcSEcCtD
Flurbiprofen—Gastrointestinal pain—Methotrexate—bone cancer	0.00011	0.000699	CcSEcCtD
Flurbiprofen—PTGS2—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000109	0.00189	CbGpPWpGaD
Flurbiprofen—Decreased appetite—Epirubicin—bone cancer	0.000109	0.000696	CcSEcCtD
Flurbiprofen—Hypotension—Doxorubicin—bone cancer	0.000109	0.000692	CcSEcCtD
Flurbiprofen—Constipation—Epirubicin—bone cancer	0.000107	0.000685	CcSEcCtD
Flurbiprofen—Pain—Epirubicin—bone cancer	0.000107	0.000685	CcSEcCtD
Flurbiprofen—Urticaria—Methotrexate—bone cancer	0.000107	0.00068	CcSEcCtD
Flurbiprofen—Body temperature increased—Methotrexate—bone cancer	0.000106	0.000676	CcSEcCtD
Flurbiprofen—Abdominal pain—Methotrexate—bone cancer	0.000106	0.000676	CcSEcCtD
Flurbiprofen—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000106	0.000675	CcSEcCtD
Flurbiprofen—Insomnia—Doxorubicin—bone cancer	0.000105	0.00067	CcSEcCtD
Flurbiprofen—Paraesthesia—Doxorubicin—bone cancer	0.000104	0.000665	CcSEcCtD
Flurbiprofen—Dyspnoea—Doxorubicin—bone cancer	0.000104	0.00066	CcSEcCtD
Flurbiprofen—Feeling abnormal—Epirubicin—bone cancer	0.000103	0.00066	CcSEcCtD
Flurbiprofen—PTGS1—Selenium Micronutrient Network—PTGS2—bone cancer	0.000103	0.00179	CbGpPWpGaD
Flurbiprofen—Somnolence—Doxorubicin—bone cancer	0.000103	0.000658	CcSEcCtD
Flurbiprofen—Gastrointestinal pain—Epirubicin—bone cancer	0.000103	0.000655	CcSEcCtD
Flurbiprofen—Dyspepsia—Doxorubicin—bone cancer	0.000102	0.000652	CcSEcCtD
Flurbiprofen—UGT2B7—Metabolism—NT5C3A—bone cancer	0.000102	0.00177	CbGpPWpGaD
Flurbiprofen—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—bone cancer	0.000102	0.00177	CbGpPWpGaD
Flurbiprofen—Decreased appetite—Doxorubicin—bone cancer	0.000101	0.000644	CcSEcCtD
Flurbiprofen—UGT1A1—Metabolism—NDUFA12—bone cancer	0.0001	0.00174	CbGpPWpGaD
Flurbiprofen—UGT1A9—Metabolism—NDUFA12—bone cancer	0.0001	0.00174	CbGpPWpGaD
Flurbiprofen—Urticaria—Epirubicin—bone cancer	9.97e-05	0.000636	CcSEcCtD
Flurbiprofen—PTGS2—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	9.95e-05	0.00172	CbGpPWpGaD
Flurbiprofen—Pain—Doxorubicin—bone cancer	9.93e-05	0.000633	CcSEcCtD
Flurbiprofen—Constipation—Doxorubicin—bone cancer	9.93e-05	0.000633	CcSEcCtD
Flurbiprofen—Body temperature increased—Epirubicin—bone cancer	9.92e-05	0.000633	CcSEcCtD
Flurbiprofen—Abdominal pain—Epirubicin—bone cancer	9.92e-05	0.000633	CcSEcCtD
Flurbiprofen—Hypersensitivity—Methotrexate—bone cancer	9.88e-05	0.00063	CcSEcCtD
Flurbiprofen—ABCC4—Hemostasis—SPARC—bone cancer	9.84e-05	0.00171	CbGpPWpGaD
Flurbiprofen—UGT2B4—Metabolism—ENO2—bone cancer	9.83e-05	0.0017	CbGpPWpGaD
Flurbiprofen—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	9.82e-05	0.0017	CbGpPWpGaD
Flurbiprofen—PTGS2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	9.76e-05	0.00169	CbGpPWpGaD
Flurbiprofen—Asthenia—Methotrexate—bone cancer	9.62e-05	0.000614	CcSEcCtD
Flurbiprofen—Feeling abnormal—Doxorubicin—bone cancer	9.57e-05	0.00061	CcSEcCtD
Flurbiprofen—Gastrointestinal pain—Doxorubicin—bone cancer	9.5e-05	0.000606	CcSEcCtD
Flurbiprofen—Pruritus—Methotrexate—bone cancer	9.49e-05	0.000605	CcSEcCtD
Flurbiprofen—Hypersensitivity—Epirubicin—bone cancer	9.25e-05	0.00059	CcSEcCtD
Flurbiprofen—Urticaria—Doxorubicin—bone cancer	9.22e-05	0.000588	CcSEcCtD
Flurbiprofen—Abdominal pain—Doxorubicin—bone cancer	9.18e-05	0.000585	CcSEcCtD
Flurbiprofen—Body temperature increased—Doxorubicin—bone cancer	9.18e-05	0.000585	CcSEcCtD
Flurbiprofen—Diarrhoea—Methotrexate—bone cancer	9.18e-05	0.000585	CcSEcCtD
Flurbiprofen—UGT2B4—Metabolism—DHFR—bone cancer	9.12e-05	0.00158	CbGpPWpGaD
Flurbiprofen—PTGS2—Spinal Cord Injury—CDK4—bone cancer	9.07e-05	0.00157	CbGpPWpGaD
Flurbiprofen—Asthenia—Epirubicin—bone cancer	9e-05	0.000574	CcSEcCtD
Flurbiprofen—ABCC4—Hemostasis—GNA11—bone cancer	9e-05	0.00156	CbGpPWpGaD
Flurbiprofen—Pruritus—Epirubicin—bone cancer	8.88e-05	0.000566	CcSEcCtD
Flurbiprofen—Dizziness—Methotrexate—bone cancer	8.87e-05	0.000566	CcSEcCtD
Flurbiprofen—ALB—Platelet activation, signaling and aggregation—SPARC—bone cancer	8.64e-05	0.0015	CbGpPWpGaD
Flurbiprofen—Diarrhoea—Epirubicin—bone cancer	8.59e-05	0.000548	CcSEcCtD
Flurbiprofen—Hypersensitivity—Doxorubicin—bone cancer	8.56e-05	0.000546	CcSEcCtD
Flurbiprofen—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	8.53e-05	0.00148	CbGpPWpGaD
Flurbiprofen—Vomiting—Methotrexate—bone cancer	8.53e-05	0.000544	CcSEcCtD
Flurbiprofen—UGT2B4—Metabolism—GNA11—bone cancer	8.52e-05	0.00148	CbGpPWpGaD
Flurbiprofen—Rash—Methotrexate—bone cancer	8.46e-05	0.000539	CcSEcCtD
Flurbiprofen—Dermatitis—Methotrexate—bone cancer	8.45e-05	0.000539	CcSEcCtD
Flurbiprofen—Headache—Methotrexate—bone cancer	8.4e-05	0.000536	CcSEcCtD
Flurbiprofen—Asthenia—Doxorubicin—bone cancer	8.33e-05	0.000531	CcSEcCtD
Flurbiprofen—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	8.32e-05	0.00144	CbGpPWpGaD
Flurbiprofen—UGT1A1—Metabolism—NT5C3A—bone cancer	8.31e-05	0.00144	CbGpPWpGaD
Flurbiprofen—UGT1A9—Metabolism—NT5C3A—bone cancer	8.31e-05	0.00144	CbGpPWpGaD
Flurbiprofen—Dizziness—Epirubicin—bone cancer	8.3e-05	0.000529	CcSEcCtD
Flurbiprofen—Pruritus—Doxorubicin—bone cancer	8.22e-05	0.000524	CcSEcCtD
Flurbiprofen—PTGS1—Metabolism—NDUFA12—bone cancer	8.17e-05	0.00142	CbGpPWpGaD
Flurbiprofen—ABCC4—Hemostasis—IL3—bone cancer	8.16e-05	0.00141	CbGpPWpGaD
Flurbiprofen—Vomiting—Epirubicin—bone cancer	7.98e-05	0.000509	CcSEcCtD
Flurbiprofen—Nausea—Methotrexate—bone cancer	7.97e-05	0.000508	CcSEcCtD
Flurbiprofen—Diarrhoea—Doxorubicin—bone cancer	7.95e-05	0.000507	CcSEcCtD
Flurbiprofen—Rash—Epirubicin—bone cancer	7.91e-05	0.000505	CcSEcCtD
Flurbiprofen—Dermatitis—Epirubicin—bone cancer	7.91e-05	0.000504	CcSEcCtD
Flurbiprofen—ALB—Platelet activation, signaling and aggregation—GNA11—bone cancer	7.9e-05	0.00137	CbGpPWpGaD
Flurbiprofen—PTGS2—Spinal Cord Injury—RB1—bone cancer	7.89e-05	0.00137	CbGpPWpGaD
Flurbiprofen—Headache—Epirubicin—bone cancer	7.86e-05	0.000501	CcSEcCtD
Flurbiprofen—UGT2B4—Metabolism—CYP3A4—bone cancer	7.73e-05	0.00134	CbGpPWpGaD
Flurbiprofen—Dizziness—Doxorubicin—bone cancer	7.68e-05	0.00049	CcSEcCtD
Flurbiprofen—Nausea—Epirubicin—bone cancer	7.45e-05	0.000475	CcSEcCtD
Flurbiprofen—Vomiting—Doxorubicin—bone cancer	7.38e-05	0.000471	CcSEcCtD
Flurbiprofen—Rash—Doxorubicin—bone cancer	7.32e-05	0.000467	CcSEcCtD
Flurbiprofen—Dermatitis—Doxorubicin—bone cancer	7.31e-05	0.000467	CcSEcCtD
Flurbiprofen—Headache—Doxorubicin—bone cancer	7.27e-05	0.000464	CcSEcCtD
Flurbiprofen—CYP2C9—Biological oxidations—CYP3A4—bone cancer	7.17e-05	0.00124	CbGpPWpGaD
Flurbiprofen—ALB—Platelet activation, signaling and aggregation—IL3—bone cancer	7.16e-05	0.00124	CbGpPWpGaD
Flurbiprofen—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	7.07e-05	0.00122	CbGpPWpGaD
Flurbiprofen—Nausea—Doxorubicin—bone cancer	6.9e-05	0.00044	CcSEcCtD
Flurbiprofen—PTGS1—Metabolism—NT5C3A—bone cancer	6.77e-05	0.00117	CbGpPWpGaD
Flurbiprofen—ALB—Transmembrane transport of small molecules—TUBB4B—bone cancer	6.71e-05	0.00116	CbGpPWpGaD
Flurbiprofen—ALB—Selenium Micronutrient Network—PTGS2—bone cancer	6.63e-05	0.00115	CbGpPWpGaD
Flurbiprofen—UGT2B4—Metabolism—GSTP1—bone cancer	6.61e-05	0.00115	CbGpPWpGaD
Flurbiprofen—PTGS2—Metabolism—NDUFA12—bone cancer	6.49e-05	0.00112	CbGpPWpGaD
Flurbiprofen—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	6.17e-05	0.00107	CbGpPWpGaD
Flurbiprofen—CYP2C9—Biological oxidations—GSTP1—bone cancer	6.13e-05	0.00106	CbGpPWpGaD
Flurbiprofen—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	6.05e-05	0.00105	CbGpPWpGaD
Flurbiprofen—ALB—Transmembrane transport of small molecules—TUBB2A—bone cancer	5.79e-05	0.001	CbGpPWpGaD
Flurbiprofen—PTGS2—Spinal Cord Injury—MMP9—bone cancer	5.69e-05	0.000985	CbGpPWpGaD
Flurbiprofen—PTGS2—Metabolism—NT5C3A—bone cancer	5.38e-05	0.000931	CbGpPWpGaD
Flurbiprofen—ABCC4—Hemostasis—PLAU—bone cancer	5.35e-05	0.000928	CbGpPWpGaD
Flurbiprofen—UGT1A3—Metabolism—ENO2—bone cancer	5.27e-05	0.000913	CbGpPWpGaD
Flurbiprofen—ALB—Metabolism—NDUFA12—bone cancer	5.25e-05	0.000909	CbGpPWpGaD
Flurbiprofen—ALB—Folate Metabolism—TP53—bone cancer	4.97e-05	0.000861	CbGpPWpGaD
Flurbiprofen—UGT1A3—Metabolism—DHFR—bone cancer	4.88e-05	0.000847	CbGpPWpGaD
Flurbiprofen—PTGS2—Spinal Cord Injury—EGFR—bone cancer	4.59e-05	0.000796	CbGpPWpGaD
Flurbiprofen—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	4.57e-05	0.000793	CbGpPWpGaD
Flurbiprofen—UGT1A3—Metabolism—GNA11—bone cancer	4.57e-05	0.000791	CbGpPWpGaD
Flurbiprofen—UGT2B7—Metabolism—ENO2—bone cancer	4.48e-05	0.000776	CbGpPWpGaD
Flurbiprofen—ALB—Hemostasis—SPARC—bone cancer	4.45e-05	0.000772	CbGpPWpGaD
Flurbiprofen—ALB—Metabolism—NT5C3A—bone cancer	4.35e-05	0.000754	CbGpPWpGaD
Flurbiprofen—CYP2C9—Metabolism—NDUFA12—bone cancer	4.3e-05	0.000744	CbGpPWpGaD
Flurbiprofen—UGT2B7—Metabolism—DHFR—bone cancer	4.15e-05	0.00072	CbGpPWpGaD
Flurbiprofen—UGT1A3—Metabolism—CYP3A4—bone cancer	4.14e-05	0.000717	CbGpPWpGaD
Flurbiprofen—ALB—Hemostasis—GNA11—bone cancer	4.07e-05	0.000706	CbGpPWpGaD
Flurbiprofen—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	3.98e-05	0.000689	CbGpPWpGaD
Flurbiprofen—UGT2B7—Metabolism—GNA11—bone cancer	3.88e-05	0.000673	CbGpPWpGaD
Flurbiprofen—PTGS2—Spinal Cord Injury—TP53—bone cancer	3.86e-05	0.000669	CbGpPWpGaD
Flurbiprofen—ALB—Hemostasis—IL3—bone cancer	3.69e-05	0.00064	CbGpPWpGaD
Flurbiprofen—UGT1A1—Metabolism—ENO2—bone cancer	3.64e-05	0.00063	CbGpPWpGaD
Flurbiprofen—UGT1A9—Metabolism—ENO2—bone cancer	3.64e-05	0.00063	CbGpPWpGaD
Flurbiprofen—CYP2C9—Metabolism—NT5C3A—bone cancer	3.56e-05	0.000617	CbGpPWpGaD
Flurbiprofen—UGT1A3—Metabolism—GSTP1—bone cancer	3.54e-05	0.000613	CbGpPWpGaD
Flurbiprofen—UGT2B7—Metabolism—CYP3A4—bone cancer	3.52e-05	0.00061	CbGpPWpGaD
Flurbiprofen—UGT2B4—Metabolism—PTGS2—bone cancer	3.42e-05	0.000593	CbGpPWpGaD
Flurbiprofen—UGT1A1—Metabolism—DHFR—bone cancer	3.38e-05	0.000585	CbGpPWpGaD
Flurbiprofen—UGT1A9—Metabolism—DHFR—bone cancer	3.38e-05	0.000585	CbGpPWpGaD
Flurbiprofen—UGT1A1—Metabolism—GNA11—bone cancer	3.15e-05	0.000547	CbGpPWpGaD
Flurbiprofen—UGT1A9—Metabolism—GNA11—bone cancer	3.15e-05	0.000547	CbGpPWpGaD
Flurbiprofen—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	3.13e-05	0.000542	CbGpPWpGaD
Flurbiprofen—UGT2B7—Metabolism—GSTP1—bone cancer	3.01e-05	0.000522	CbGpPWpGaD
Flurbiprofen—PTGS1—Metabolism—ENO2—bone cancer	2.97e-05	0.000514	CbGpPWpGaD
Flurbiprofen—UGT1A1—Metabolism—CYP3A4—bone cancer	2.86e-05	0.000496	CbGpPWpGaD
Flurbiprofen—UGT1A9—Metabolism—CYP3A4—bone cancer	2.86e-05	0.000496	CbGpPWpGaD
Flurbiprofen—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.85e-05	0.000493	CbGpPWpGaD
Flurbiprofen—PTGS2—Disease—ENO2—bone cancer	2.81e-05	0.000487	CbGpPWpGaD
Flurbiprofen—PTGS1—Metabolism—DHFR—bone cancer	2.75e-05	0.000477	CbGpPWpGaD
Flurbiprofen—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.62e-05	0.000455	CbGpPWpGaD
Flurbiprofen—PTGS2—Disease—DHFR—bone cancer	2.61e-05	0.000452	CbGpPWpGaD
Flurbiprofen—PTGS1—Metabolism—GNA11—bone cancer	2.57e-05	0.000446	CbGpPWpGaD
Flurbiprofen—UGT1A1—Metabolism—GSTP1—bone cancer	2.45e-05	0.000424	CbGpPWpGaD
Flurbiprofen—UGT1A9—Metabolism—GSTP1—bone cancer	2.45e-05	0.000424	CbGpPWpGaD
Flurbiprofen—ALB—Hemostasis—PLAU—bone cancer	2.42e-05	0.00042	CbGpPWpGaD
Flurbiprofen—PTGS2—Metabolism—ENO2—bone cancer	2.35e-05	0.000408	CbGpPWpGaD
Flurbiprofen—PTGS1—Metabolism—CYP3A4—bone cancer	2.33e-05	0.000404	CbGpPWpGaD
Flurbiprofen—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.32e-05	0.000402	CbGpPWpGaD
Flurbiprofen—PTGS2—Metabolism—DHFR—bone cancer	2.18e-05	0.000379	CbGpPWpGaD
Flurbiprofen—ABCC4—Hemostasis—TP53—bone cancer	2.15e-05	0.000373	CbGpPWpGaD
Flurbiprofen—PTGS2—Metabolism—GNA11—bone cancer	2.04e-05	0.000354	CbGpPWpGaD
Flurbiprofen—PTGS1—Metabolism—GSTP1—bone cancer	1.99e-05	0.000346	CbGpPWpGaD
Flurbiprofen—ALB—Metabolism—ENO2—bone cancer	1.9e-05	0.00033	CbGpPWpGaD
Flurbiprofen—PTGS2—Disease—TGFBR2—bone cancer	1.89e-05	0.000328	CbGpPWpGaD
Flurbiprofen—PTGS2—Metabolism—CYP3A4—bone cancer	1.85e-05	0.000321	CbGpPWpGaD
Flurbiprofen—UGT1A3—Metabolism—PTGS2—bone cancer	1.83e-05	0.000318	CbGpPWpGaD
Flurbiprofen—ALB—Metabolism—DHFR—bone cancer	1.77e-05	0.000306	CbGpPWpGaD
Flurbiprofen—ALB—Metabolism—GNA11—bone cancer	1.65e-05	0.000286	CbGpPWpGaD
Flurbiprofen—PTGS2—Metabolism—GSTP1—bone cancer	1.58e-05	0.000274	CbGpPWpGaD
Flurbiprofen—UGT2B7—Metabolism—PTGS2—bone cancer	1.56e-05	0.00027	CbGpPWpGaD
Flurbiprofen—CYP2C9—Metabolism—ENO2—bone cancer	1.56e-05	0.00027	CbGpPWpGaD
Flurbiprofen—ALB—Metabolism—CYP3A4—bone cancer	1.5e-05	0.000259	CbGpPWpGaD
Flurbiprofen—ALB—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.49e-05	0.000258	CbGpPWpGaD
Flurbiprofen—CYP2C9—Metabolism—DHFR—bone cancer	1.45e-05	0.000251	CbGpPWpGaD
Flurbiprofen—CYP2C9—Metabolism—GNA11—bone cancer	1.35e-05	0.000234	CbGpPWpGaD
Flurbiprofen—PTGS2—Disease—KIT—bone cancer	1.29e-05	0.000223	CbGpPWpGaD
Flurbiprofen—ALB—Metabolism—GSTP1—bone cancer	1.28e-05	0.000222	CbGpPWpGaD
Flurbiprofen—UGT1A1—Metabolism—PTGS2—bone cancer	1.27e-05	0.00022	CbGpPWpGaD
Flurbiprofen—UGT1A9—Metabolism—PTGS2—bone cancer	1.27e-05	0.00022	CbGpPWpGaD
Flurbiprofen—CYP2C9—Metabolism—CYP3A4—bone cancer	1.23e-05	0.000212	CbGpPWpGaD
Flurbiprofen—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.22e-05	0.000211	CbGpPWpGaD
Flurbiprofen—PTGS2—Disease—BRAF—bone cancer	1.21e-05	0.00021	CbGpPWpGaD
Flurbiprofen—CYP2C9—Metabolism—GSTP1—bone cancer	1.05e-05	0.000182	CbGpPWpGaD
Flurbiprofen—PTGS1—Metabolism—PTGS2—bone cancer	1.03e-05	0.000179	CbGpPWpGaD
Flurbiprofen—PTGS2—Disease—MDM2—bone cancer	1.02e-05	0.000176	CbGpPWpGaD
Flurbiprofen—ALB—Hemostasis—TP53—bone cancer	9.74e-06	0.000169	CbGpPWpGaD
Flurbiprofen—PTGS2—Disease—EGFR—bone cancer	6.94e-06	0.00012	CbGpPWpGaD
Flurbiprofen—ALB—Metabolism—PTGS2—bone cancer	6.63e-06	0.000115	CbGpPWpGaD
Flurbiprofen—CYP2C9—Metabolism—PTGS2—bone cancer	5.43e-06	9.41e-05	CbGpPWpGaD
